Loading...

Home
ETF
NRSN

NRSN

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

NRSN News

NeuroSense Participates in ALS Expert Webinar

1d agoPRnewswire

NeuroSense's ALS Study Achieves Breakthrough

Jun 29 2026NASDAQ.COM

NeuroSense Achieves Breakthrough in ALS Study

Jun 29 2026PRnewswire

PrimeC Shows Positive Biomarker Findings in Alzheimer's Disease Study

Jun 25 2026PRnewswire

NeuroSense Announces New Developments in ALS Research

Jun 22 2026PRnewswire

NeuroSense Secures $600,000 in Private Placement Financing

Apr 28 2026PRnewswire

NeuroSense Secures Brazilian Patent to Support PrimeC Development

Apr 06 2026PRnewswire

NeuroSense Faces Nasdaq Compliance Warning

Apr 03 2026seekingalpha

NeuroSense Faces Nasdaq Compliance Warning

Apr 03 2026PRnewswire

NeuroSense Reports FY 2025 Financial Results with Patent Grant

Mar 31 2026seekingalpha

NeuroSense Reports 2025 Financial Results and Business Update

Mar 31 2026PRnewswire

NeuroSense to Present PrimeC Data at AD/PD 2026 Conference

Mar 18 2026PRnewswire

NeuroSense Publishes ALS Clinical Trial Results in JAMA Neurology

Mar 16 2026PRnewswire

Wall Street Analysts Adjust Ratings on Key Stocks

Mar 10 2026Benzinga

NeuroSense Reports New ALS Treatment Data

Mar 09 2026PRnewswire

NeuroSense Releases New ALS Treatment Data

Feb 18 2026PRnewswire